Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Palladone 10 mg/ml solution for injection or infusion

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Hydromorphone hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Hydromorphone hydrochloride
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for This medicine has been prescribed for you for the relief of severe pain. It contains hydromorphone, which belongs to a class of medicines called opioids, which are 'pain relievers'. This medicine has been prescribed for you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking this medicine suddenly. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely.

What you need to know before you take it

e Palladone injection Do not use Palladone injection if you:

  • are allergic to hydromorphone or to any of the other ingredients of this medicine (listed in section 6);
  • have breathing problems, such as severe chronic obstructive airways disease, respiratory depression or severe asthma. Symptoms may include breathlessness, coughing or breathing more slowly and weakly than expected;
  • have a heart problem after long-term lung disease (cor pulmonale);
  • have severe pain in your abdomen;
  • have a condition where the small bowel does not work properly (paralytic ileus);
  • are taking a type of medicine known as a monoamine oxidase inhibitor (examples include tranylcypromine, phenelzine, isocarboxazid, moclobemide and linezolid), or you have taken this type of medicine in the last two weeks. Palladone injection must not be used if the patient is in a coma.

Warnings and precautions Talk to your doctor or pharmacist before using Palladone injection if you:

  • are or have ever been addicted to opioids, alcohol, prescription medicines, or illegal drugs;
  • have previously suffered from withdrawal symptoms such as agitation, anxiety, shaking or sweating, when you have stopped taking alcohol or drugs;
  • feel you need to take more of Palladone to get the same level of pain relief, this may mean you are becoming tolerant to the effects of this medicine or are becoming addicted to it. Speak to your prescriber who will discuss your treatment and may change your dose or switch you to an alternative pain reliever;
  • have a head injury (due to the risk of increased brain pressure);
  • suffer from seizures, fits or convulsions;
  • suffer from a mental disorder as a result of an intoxication (toxic psychosis);
  • have low blood pressure associated with low circulating blood volume (hypotension with hypovolaemia);
  • are feeling light-headed or faint;
  • have problems with your gall bladder;
  • have inflammation of the pancreas (pancreatitis);
  • have any bowel problems (such as obstructive or inflammatory bowel disease);
  • have prostate problems (such as difficulties in passing urine);
  • have poor adrenal gland function (e.g. Addison's disease).
  • have an under-active thyroid gland (hypothyroidism);
  • have a chronic obstructive airway disease (such as COPD) or reduced pulmonary function;
  • suffer from a debilitated general condition or are elderly;
  • suffer from severe kidney problems (including ureteric colic);
  • suffer from severe liver problems;
  • suffer from constipation. This medicine may cause breathing problems or worsen already existing problems while sleeping. These problems may include pauses in breathing during sleep, being awoken by shortness of breath, difficulty staying asleep or excessive daytime drowsiness. If you or someone else observes these symptoms contact your doctor. Your doctor may want to lower your dose. Tolerance, dependence and addiction This medicine contains hydromorphone, which is an opioid. It can cause dependence and/or addiction . This medicine contains hydromorphone which is an opioid medicine. Repeated use of opioid painkillers may result in the drug being less effective (you become accustomed to it). Repeated use of Palladone injection may lead to dependence and abuse which may result in life threatening overdose. If you have concern that you may become dependent on Palladone injection, it is important that you consult your doctor. Using this medicine regularly, particularly for a long time, can lead to addiction. Your prescriber should have explained how long you will be using it for and when it is appropriate to stop, how to do this safely. Dependence or addiction can make you feel that you are no longer in control of how much medicine you need to take or how often you need to take it. The risk of becoming dependent or addicted varies from person to person. You may have a greater risk of becoming dependent or addicted on Palladone injection if:

–

You or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or illegal drugs ("addiction"). You are a smoker. You have ever had problems with your mood (depression, anxiety or a personality disorder) or have been treated by a psychiatrist for other mental illnesses.

If you notice any of the following signs whilst taking Palladone injection, it could be a sign that you have become dependent or addicted: –

You need to take the medicine for longer than advised by your doctor. You need to take more than the recommended dose. You might feel that you need to carry on taking your medicine, even when it doesn't help to relieve your pain. You are using the medicine for reasons other than prescribed, for instance, 'to stay calm' or 'help you sleep'. You have made repeated, unsuccessful attempts to quit or control the use of the medicine. When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again ('withdrawal effects').

If you notice any of these signs, speak to your doctor to discuss the best treatment pathway for you, including when it is appropriate to stop and how to stop safely (see section 3, If you stop taking { Palladone injection}). Rarely, increasing the dose of this medicine can make you more sensitive to pain. If this happens, you need to speak to your prescriber about your treatment. Addiction can cause withdrawal symptoms when you stop taking this medicine. Withdrawal symptoms can include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, loss of appetite, shaking, shivering or sweating. Your doctor will discuss with you how to gradually reduce your dose before stopping the medicine. It is important that you do not stop taking the medicine suddenly as you will be more likely to experience withdrawal symptoms. Opioids should only be used by those they are prescribed for. Do not give your medicine to anyone else. Taking higher doses or more frequent doses of opioid may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death. You may experience hormonal changes whilst using this medicine. Your doctor may want to monitor these changes. If this information applies to you or formerly applied to you, please speak to your doctor. Palladone injection is not recommended for children under 12 years of age. The major risk of opioid excess is difficulty in breathing (respiratory depression). Please tell your doctor if you experience small bowel problems (paralytic ileus) during treatment with this medicine. He or she will take appropriate measures. If you are going to have an operation, please tell the doctor at the hospital that you are using this medicine as they may need to adjust the amount of injection you are given.

The use of this medicine may produce positive results in doping controls. Other medicines and Palladone injection Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. When taken with some other medicines or alcohol, the side effects of Palladone injection (such as drowsiness, breathing problems, constipation, dry mouth, difficulty in passing urine) or the other medicine may be altered. Tell your doctor if you:

  • are taking medicines to treat anxiety (for example tranquillisers);
  • have been given an anaesthetic (for example a barbiturate);
  • are taking medicines to help you sleep (benzodiazepines, hypnotics or sedatives);
  • are taking medicines to treat psychiatric or mental disorders (neuroleptics or psychotropics);
  • are taking medicines to treat depression (antidepressants);
  • are taking medicines used to stop you feeling sick or being sick (antiemetics);
  • are taking medicines used to prevent or relieve the symptoms of an allergy (antihistamines);
  • are taking medicines to treat Parkinson's disease;
  • are taking other strong analgesics or 'painkillers', or have recently taken another painkiller from the opioid class. Concomitant use of Palladone injection and sedative medicines such as benzodiazepines or related drugs increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible. The concomitant use of opioids and drugs used to treat epilepsy, nerve pain or anxiety (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression and may be life-threatening. However if your doctor does prescribe Palladone injection together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor. Please tell your doctor about all sedative medicines you are taking, and follow your doctor's dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms. Sleep-related breathing disorders Palladone injection can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor. Do not take this medicine if you are taking a specific type of medicine known as a monoamine oxidase inhibitor, or you have taken this type of medicine in the last two weeks. Palladone injection with food, drink and alcohol Drinking alcohol during your treatment with this medicine may make you drowsy. If you are affected you should avoid drinking alcohol.

Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. Pregnancy Do not use Palladone injection if you are pregnant or think you might be pregnant unless you have discussed this with your doctor and the benefits of treatment are considered to outweigh the potential harm to the baby. If you use Palladone injection during pregnancy your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated, such as high-pitched cry, jitteriness, fits, poor feeding and diarrhoea. If you use this medicine during labour, uterine contractility may be impaired. In addition slow and shallow breathing (respiratory depression) may occur in the newborn infant. Breast-feeding Do not use Palladone injection while you are breastfeeding as hydromorphone passes into breast milk and will affect your baby. Driving and using machines This medicine may make you drowsy and thus impair your ability to drive and use machines. This applies particularly:

  • at the beginning of treatment;
  • if your dose is increased;
  • if you have switched to this medicine from a different opioid.
  • if you drink alcohol or use medicines which influence your brain function. You should consult your doctor before driving or using machinery. This medicine can affect your ability to drive as it may make you sleepy or dizzy.
  • Do not drive while taking this medicine until you know how it affects you.
  • It is an offence to drive while you have this medicine in your body over a specified limit unless you have a defence (called the 'statutory defence').
  • This defence applies when: o The medicine has been prescribed to treat a medical or dental problem; and o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine.
  • Please note that it is still an offence to drive if you are unfit because of the medicine (i.e. your ability to drive is being affected). Details regarding a new driving offence concerning driving after drugs have been taken in the UK may be found here: https://www.gov.uk/drug-driving-law Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine. Palladone injection contains sodium This medicine contains less than 1 mmol sodium (23 mg) per ml, i.e. essentially "sodium-free".

How to take it

Palladone injection Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

A doctor or nurse will usually prepare and administer the injection for you. Your doctor will decide how much Palladone injection you require based on:

  • the severity of your pain;
  • the dose of painkiller you have previously been given;
  • your age and weight. Your doctor will increase the amount of this medicine you are given until your pain is relieved. If you find that you are still in pain whilst undergoing treatment with this medicine discuss this with your doctor. You should not use Palladone 10 mg, injection as initial opioid therapy. This higher strength may only be used as individual doses if you have no longer sufficiently responded to lower doses of hydromorphone preparations (Palladone 2 mg) or comparably strong analgesics as part of long term pain therapy. The usual starting doses of Palladone injection are as follows: Use in adults and adolescents (older than 12 years of age)
  • As a single injection into a vein, the usual dose is 1 to 1.5 mg given slowly over 2 to 3 minutes. This can be repeated every 3 to 4 hours.
  • As a single injection through a fine needle into the tissue under the skin, the usual dose is 1 to 2 mg. This can be repeated every 3 to 4 hours.
  • As an infusion into a vein or through a fine needle into the tissue under the skin, the usual starting dose is 0.15 to 0.45 mg/hour (or 0.004 mg/kg bodyweight/hour).
  • If given by patient controlled analgesia (PCA), the usual recommended bolus dose is 0.2 mg with a stop interval of 5 to 10 minutes. Use in children (under 12 years of age) Palladone injection is not recommended for children under 12 years of age. Use in elderly patients (over 75 years of age) A lower dosage might be enough for adequate pain relief in elderly patients. Use in patients with liver and kidney problems If you suffer from liver or kidney problems, you may require less of this medicine in order to relieve your pain. Route of administration A doctor or nurse will usually administer Palladone injection for you. This medicine is intended for injection or infusion into a vein (intravenous = IV) or through a fine needle under the skin (subcutaneous = SC). Duration of treatment This medicine should only be used as long as necessary. Your doctor should have discussed with you how long your treatment with Palladone will last. They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine.

If you get long term treatment, your doctor should verify regularly whether you still need this medicine. Do not stop the treatment without talking to your doctor (see "If you stop using Palladone injection"). If you use more Palladone injection than you should Call your doctor, hospital or an ambulance straight away as the patient may need emergency treatment in hospital. In severe cases an overdose may lead to unconsciousness, a brain disorder (known as toxic leukoencephalopathy), pneumonia caused by inhaling vomit or foreign matter (symptoms may include breathlessness, cough and fever) or even death. The following symptoms may occur after an overdose:

  • pin point pupils;
  • slowing of heartbeat;
  • respiratory problems;
  • low blood pressure;
  • unconsciousness leading to coma.
  • breathlessness, cough and fever If you have used too much Palladone injection under no circumstances should you put yourself in a situation that requires you to be alert e.g. driving a car. When seeking medical attention make sure that you take this leaflet and any remaining ampoules with you to show to the doctor. If you forget to use Palladone injection Please use Palladone injection as soon as you notice that you forgot a dose. Never double the dose. If you forget to use Palladone injection or use a smaller dose than prescribed, this will lead to unsatisfactory and/or insufficient pain relief. If you stop using Palladone injection Do not suddenly stop taking this medicine. If you want to stop taking this medicine discuss this with your doctor first. They will tell you how to do this, usually by reducing the dose gradually so that any unpleasant withdrawal effects are kept to a minimum. Withdrawal symptoms such as restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating may occur if you suddenly stop taking this medicine. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. This medicine can cause allergic reactions (hypersensitivity reactions). The incidence of serious allergic reactions (anaphylactic reactions) is not known. Tell your doctor immediately if you get any sudden wheeziness, difficulties in breathing, swelling of the eyelids, face, lips, mouth or throat, or any rash or itching especially those covering your whole body. Difficulty in breathing (respiratory depression) is the chief hazard of an opioid overdose. Drug withdrawal When you stop using Palladone injection you may experience drug withdrawal symptoms, which include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating.

How do I know if I am addicted? If you notice any of the following signs whilst using Palladone injection it could be a sign that you have become addicted.

  • You need to use the medicine for longer than advised by your prescriber;
  • You feel you need to use more than the recommended dose;
  • You are using the medicine for reasons other than prescribed;
  • When you stop using the medicine you feel unwell, and you feel better once using the medicine again. If you notice any of these signs it is important you talk to your doctor. Most people will have constipation when using this medicine. Increasing the amount of fibre (fruit, vegetables, wholemeal bread, pasta, brown rice) and fluids you eat and drink may help reduce the problem, but if necessary your doctor may prescribe a laxative. You may feel sick or vomit (be sick) when you use this medicine, this should normally wear off after a few days however your doctor can prescribe an anti-vomiting medicine if it continues to be a problem. Very common side effects (may affect more than 1 in 10 people)
  • dizziness, feel more sleepy than normal
  • constipation, feel sick Common side effects (may affect up to 1 in 10 people)
  • confusion, anxiety, sleeplessness
  • headache
  • dry mouth, vomiting (be sick)
  • itchy skin, sweating
  • urgency in passing urine
  • a feeling of unusual weakness
  • loss of appetite
  • abdominal pain or discomfort
  • skin reactions at the injection site Uncommon side effects (may affect up to 1 in 100 people)
  • feeling of extreme happiness, hallucinations
  • shaking, muscle spasms, tingling in the hands or feet
  • blurred vision
  • low blood pressure
  • indigestion
  • rash
  • decreased sexual drive, impotence
  • withdrawal symptoms such as agitation, anxiety, nervousness, difficulty in sleeping, being unusually overactive, shaking and gastrointestinal problems
  • tiredness, generally feeling unwell
  • swelling of hands, ankles or feet
  • agitation, depression, nightmares
  • shortness of breath
  • diarrhoea, changes in taste
  • difficulty in passing urine
  • a worsening in liver function tests (seen in a blood test)

Rare side effects (may affect up to 1 in 1,000 people)

  • sedation, lack of energy
  • slow, fast or irregular heartbeat
  • difficulty in breathing or wheezing
  • a worsening in pancreas function tests (seen in a blood test) Very rare side effects (may affect up to 1 in 10,000 people)
  • irritation and hardening of the skin at the injection site (particularly after repeated subcutaneous administration)

Possible side effects

with unknown frequency (frequency cannot be estimated from the available data)

  • dependence and addiction (see section 'How do I know if I am addicted?')
  • drug tolerance
  • unpleasant or uncomfortable mood
  • reduction in size of the pupils in the eye
  • an increase in sensitivity to pain (hyperalgesia; see "Warnings and precautions" in section 2)
  • seizures, fits or convulsions
  • uncontrolled muscle movements
  • facial flushing (redness of the face)
  • a condition where the small bowel (part of your gut) does not work properly (paralytic ileus)
  • itching rash (hives)
  • withdrawal symptoms in babies born to mothers who have used hydromorphone (see "Pregnancy and breastfeeding" in section 2).
  • sleep apnoea (breathing pauses during sleep). Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Palladone injection Keep this medicine out of the sight and reach of children. Keep the ampoules in the outer carton in order to protect from light. Do not use this medicine after the expiry date which is stated on the carton and the ampoule label after "EXP". The expiry date refers to the last day of that month. From a microbiological point of view the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8°C, unless opening/ dilution has taken place in controlled and validated aseptic conditions. The medicine is to be visually inspected prior to use. Only clear solutions free from particles should be used. Do not throw away any medicines via wastewater or household waste. Ask you pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

Contents of the pack and other information

What Palladone injection contains: Palladone 2 mg/ml injection:

  • The active substance is hydromorphone hydrochloride. Each ampoule contains 2 mg hydromorphone hydrochloride (corresponding to 1.77 mg hydromorphone) in 1 ml solution. Palladone 10 mg/ml injection:
  • The active substance is hydromorphone hydrochloride. Each ampoule contains 10 mg hydromorphone hydrochloride (corresponding to 8.87 mg hydromorphone) in 1 ml solution. The other ingredients are:
  • Citric acid anhydrous
  • Sodium citrate
  • Sodium chloride
  • Sodium hydroxide
  • Hydrochloric acid
  • Water for injections What Palladone injection looks like and contents of the pack Palladone injection is a clear, colourless to pale yellow, pH 4.0 solution for injection or infusion supplied in clear glass ampoules, available in packs of 5 x 1 ml ampoules. Marketing Authorisation Holder Napp Pharmaceuticals Limited, Cambridge Science Park, Milton Road, Cambridge CB4 0GW, UK. Manufacturer Bard Pharmaceuticals Limited, Cambridge Science Park, Milton Road, Cambridge CB4 0GW, UK. This leaflet is also available in large print, Braille or as an audio CD. To request a copy, please call the RNIB Medicine Information line (free of charge) on: 0800 198 5000 You will need to give details of the product name and reference number. These are as follows: Product name: Palladone solution for injection or infusion Reference number: 16950/0163 This leaflet was last revised in November 2025. ® Palladone and the NAPP logo are registered trade marks. © 2012-2024 Napp Pharmaceuticals Limited

Information for Health Professionals Palladone® 2 mg/ml and 10 mg/ml solution for injection or infusion Hydromorphone hydrochloride This leaflet provides technical information for the healthcare professional about Palladone 2 mg/ml and 10 mg/ml, solutions for injection or infusion. Posology and method of administration Method of administration Intravenous injection or infusion Subcutaneous injection or infusion The medicinal product is to be visually inspected prior to use. Only clear solutions free from particles should be used. After opening, this medicinal product should be used immediately. Posology The dosing of Palladone injection has to be adjusted to the patients' severity of pain and to their individual response. The dose should be titrated until optimum analgesic effect is achieved. While the dose to be administered should be sufficient to achieve appropriate analgesia, the aim should also be to keep the dose as small as possible in the individual case. Palladone injection should not be administered for longer than absolutely necessary. If long-term treatment is required careful and regular monitoring should control whether and to what degree further treatment is necessary. When a patient no longer requires therapy with hydromorphone, it may be advisable to taper the daily dose gradually to prevent withdrawal symptoms. Age Bolus Adults and adolescents (>12 years) subcutaneous (s.c.) use 1-2 mg s.c. every 3-4 hours intravenous (i.v.) use PCA (s.c. and i.v.) Paediatric population (<12 years)

Infusion 0.15-0.45 mg/h 0.004 mg/kg bodyweight/h 0.15-0.45 mg/h 0.004 mg/kg bodyweight/h

1-1.5 mg i.v. every 3-4 hours to be injected slowly over at least 2-3 minutes 0.2 mg bolus, stop interval 5-10 min. Not recommended

Paediatric population Palladone injection is not recommended for use in children under 12 years of age as the safety and efficacy has not yet been established. No data are available. Elderly patients Elderly patients (as a rule over 75 years) may require a lower dosage than other adults to achieve adequate analgesia.

Patients with hepatic and/or renal impairment These patients may require lower doses than other patient groups to achieve adequate analgesia. They should be carefully titrated to clinical effect. Cessation of therapy When a patient no longer requires therapy with hydromorphone, it may be advisable to taper the daily dose gradually to prevent withdrawal symptoms. Special precautions for disposal and other handling Chemical and physical in-use stability has been demonstrated for 7 days at 4°C, 25°C and 37°C except for diluted solutions in polycarbonate syringes which should not be stored beyond 24 hours. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8 C, unless dilution has taken place in controlled and validated aseptic conditions. No evidence of incompatibility was observed between Palladone injection and representative brands of injectable forms of the following drugs, when stored in high and low dose combinations in polypropylene syringes over a 24 hour period at ambient temperature (25°C). Hyoscine butylbromide Hyoscine hydrobromide Dexamethasone sodium phosphate Haloperidol Midazolam hydrochloride Metoclopramide hydrochloride Levomepromazine hydrochloride Glycopyrronium bromide Ketamine hydrochloride No evidence of incompatibility was observed between Palladone injection, undiluted or diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion, glucose 50 mg/ml (5%) solution for infusion or water for injections, and representative brands of polypropylene syringes, polyethylene and PVC tubing and PVC or EVA infusion bags. Incompatibilities were observed with diluted solutions of 50 mg/ml when stored in polycarbonate syringes beyond 24 hours at 25°C. Whereas no evidence of incompatibility was found when the same preparations were stored at 4°C up to 7 days. The ampoules should be stored in the outer carton in order to protect from light. Inappropriate handling of the undiluted solution after opening of the original ampoule, or of the diluted solutions may compromise the sterility of the product. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. This leaflet was last revised in November 2025. ® Palladone and the NAPP logo are Registered Trade Marks. © 2012-2024 Napp Pharmaceuticals Limited

Frequently asked questions about Palladone 10 mg/ml solution for injection or infusion

How do I take Palladone 10 mg/ml solution for injection or infusion?

Palladone 10 mg/ml solution for injection or infusion comes as injection containing 10mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Palladone 10 mg/ml solution for injection or infusion?

The active substance in Palladone 10 mg/ml solution for injection or infusion is hydromorphone hydrochloride.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Palladone 10 mg/ml solution for injection or infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Palladone 10 mg/ml solution for injection or infusion without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Hydromorphone hydrochloride (6 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

For the relief of severe pain in cancer.

Palladone injection is indicated in adults and adolescents aged >12 years.

4.2. Posology and method of administration

Method of administration

Intravenous injection or infusion

Subcutaneous injection or infusion

The medicinal product is to be visually inspected prior to use. Only clear solutions free from particles should be used.

After opening, this medicinal product should be used immediately (please refer to section 6.3).

For instructions on dilution of the medicinal product before administration, see section 6.6.

Posology

The dosing of Palladone injection has to be adjusted to the patients' severity of pain and to their individual response. The dose should be titrated until optimum analgesic effect is achieved.

While the dose to be administered should be sufficient to achieve appropriate analgesia, the aim should also be to keep the dose as small as possible in the individual case.

Duration of treatment:

Palladone injection should not be administered longer than absolutely necessary.

Treatment goals and discontinuation:

Before initiating treatment with Palladone injection, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines. During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed in order to minimise the risk of addiction and drug withdrawal syndrome. When a patient no longer requires therapy with hydromorphone, it may be advisable to taper the daily dose gradually to prevent withdrawal symptoms. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).

Palladone 10 mg/ml injection is not suitable for initial opioid therapy. This higher strength may only be used as individual doses in patients who have no longer sufficiently responded to lower doses of hydromorphone preparations (Palladone 2 mg) or comparably strong analgesics within the scope of chronic pain therapy. The reservoir of a pain pump can also be filled with individual doses of 10 mg/ml as the dose control is secured by the pump calibration.

Age

Bolus

Infusion

Adults and adolescents (> 12 years)

subcutaneous (s.c.) use

1-2 mg s.c. every 3-4 hours

0.15-0.45 mg/h 0.004 mg/kg bodyweight/h

intravenous (i.v.) use

1-1.5 mg i.v. every 3-4 hours to be injected slowly over at least 2-3 minutes

0.15-0.45 mg/h 0.004 mg/kg bodyweight/h

PCA (s.c. and i.v.)

0.2 mg bolus, stop interval 5-10 min.

Paediatric population (< 12 years)

Not recommended

Transferring patients between oral and parenteral hydromorphone:

Switching patients from parenteral hydromorphone to oral hydromorphone should be guided by the sensitivity of the individual patient. The oral starting dose should not be overestimated (for oral bioavailability see section 5.2).

Paediatric population:

Palladone injection is not recommended for use in children under 12 years of age as the safety and efficacy has not yet been established. No data are available.

Elderly patients

Elderly patients (as a rule over 75 years) may require a lower dosage than other adults to achieve adequate analgesia.

Patients with hepatic and/or renal impairment

These patients may require lower doses than other patient groups to achieve adequate analgesia. They should be carefully titrated to clinical effect (see Section 5.2).

4.3. Contraindications

Hydromorphone is contra-indicated in patients with:

• Known hypersensitivity to hydromorphone or to any of the excipients listed in section 6.1.

• Severe respiratory depression with hypoxia and/or hypercapnia

• Severe chronic obstructive pulmonary disease

• Severe bronchial asthma

• Cor pulmonale,

• Coma

• Acute abdomen

• Paralytic ileus

• Concurrent administration of mono-amine oxidase inhibitors or within two weeks of discontinuation of their use.

4.4. Special warnings and precautions for use

Hydromorphone should be used with caution in the debilitated elderly and in patients with:

• Severely impaired respiratory function

• Sleep apnoea

• CNS depressants co-administration (see below and section 4.5)

• Head injury, intracranial lesions or increased intracranial pressure, reduced level of consciousness of uncertain origin

• Hypotension with hypovolaemia

• Pancreatitis

• Hypothyroidism

• Toxic psychosis

• Prostatic hypertrophy

• Adrenocortical insufficiency (e.g., Addison's disease)

• Severely impaired renal function

• Severely impaired hepatic function

• Convulsive disorders

• Alcoholism

• Delirium tremens

• Biliary tract diseases, biliary or ureteric colic

• Obstructive or inflammatory bowel disorders

• Reduced respiratory reserve

• Constipation

In all these patients, reduced dosage may be advisable.

Sleep-related breathing disorders

The major risk of opioid excess is respiratory depression.

Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent manner (see section 4.8). Opioids may also cause worsening of pre-existing sleep apnoea (see section 4.8). In patients who present with CSA, consider decreasing the total opioid dosage.

Risk from concomitant use of sedative medicines such as benzodiazepines (and other CNS depressants)

Concomitant use of Palladone injection and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Palladone injection concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.

The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).

Tolerance and Opioid Use Disorder (abuse and dependence)

Tolerance, physical and psychological dependence may develop upon repeated administration of opioids such as hydromorphone.

Repeated use of Palladone injection can lead to Opioid Use Disorder (OUD). A higher dose and longer duration of opioid treatment can increase the risk of developing OUD. Abuse or intentional misuse of Palladone injection may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).

Before initiating treatment with Palladone injection and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see section 4.2). Before and during treatment the patient should also be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician.

Patients will require monitoring for signs of drug-seeking behaviour (e.g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.

Drug dependence, tolerance and potential for abuse

For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses. The risks are increased in individuals with current or past history of substance misuse disorder (including alcohol misuse) or mental health disorder (e.g. major depression).

Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse.

A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions.

Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient.

Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.

Patients should be closely monitored for signs of misuse, abuse or addiction.

The clinical need for analgesic treatment should be reviewed regularly.

Drug withdrawal syndrome

Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with hydromorphone.

Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.

The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.

If women take this drug during pregnancy there is a risk that their newborn infants will experience neonatal withdrawal syndrome.

Hyperalgesia

Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.

Palladone injection should not be used where the occurrence of paralytic ileus is possible. Should paralytic ileus be suspected or occur during use, hydromorphone treatment must be discontinued immediately.

Palladone injection should be used with caution pre- or intraoperatively and within the first 24 hours postoperatively.

Patients about to undergo additional pain-relieving procedures (e.g. surgery, plexus blockade) should not receive hydromorphone for 4 hours prior to the intervention. If further treatment with Palladone injection is indicated, the dosage should be adjusted to the post-operative requirement.

Opioids, such as hydromorphone, may influence the hypothalamic-pituitary-adrenal or –gonadal axes. Some changes that can be seen include an increase in serum prolactin, and decreases in plasma cortisol and testosterone. Clinical symptoms may be manifest from these hormonal changes.

It should be emphasised that patients, once adjusted (titrated) to an effective dose of a specific opioid, should not be changed to other opioid analgesics without clinical assessment and careful retitration as necessary. Otherwise a continuous analgesic action is not ensured.

This medicinal product contains less than 1 mmol sodium (23 mg) per ml, i.e. essentially “sodium-free”.

4.5. Interaction with other medicinal products and other forms of interaction

Central nervous system (CNS):

The concomitant use of opioids with sedative medicines such as benzodiazepines or other drugs that depress the CNS increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4). Drugs which depress the CNS include, but are not limited to: other opioids, anxiolytics, hypnotics and sedatives (including benzodiazepines), anaesthetics (e.g. barbiturates), antiemetics, antidepressants, antipsychotics (e.g. phenothiazines), antihistamines and alcohol.

Alcohol may also enhance the pharmacodynamic effects of hydromorphone; concomitant use should be avoided.

The concomitant use of opioids and gabapentinoids (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression and death.

Medicinal products with an anticholinergic effect (e.g. psychotropics, antiemetics, antihistamines or antiparkinsonian medicinal products) may enhance the anticholinergic undesirable effects of opioids (e.g. constipation, dry mouth or urinary retention).

Concurrent administration of hydromorphone and mono-amine oxidase inhibitors or within two weeks of discontinuation of their use is contraindicated (see section 4.3).

No interaction studies have been performed.

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no well-controlled studies of hydromorphone in pregnant women.

Hydromorphone should not be used in pregnancy unless clearly necessary.

Palladone injection is not recommended during pregnancy and labour due to impaired uterine contractility. Regular use in pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate.

If opioid use is required for a prolonged period in pregnant women, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.

Breast-feeding

Administration to nursing women is not recommended as hydromorphone is excreted into breast milk in low amounts and may cause respiratory depression in the infant.

Fertility

Non clinical toxicology studies in rats have not shown any effects on male or female fertility or sperm parameters.

4.7. Effects on ability to drive and use machines

Hydromorphone may impair the ability to drive and use machines. This is particularly likely at the initiation of treatment with hydromorphone, after dose increase or product rotation and if hydromorphone is combined with alcohol or other CNS depressant substances. Patients stabilised on a specific dosage will not necessarily be restricted. Patients should therefore consult with their physician whether driving or the use of machinery is permitted.

This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:

o The medicine is likely to affect your ability to drive.

o Do not drive until you know how the medicine affects you.

o It is an offence to drive while you have this medicine in your body over a specified limit unless you have a defence (called the 'statutory defence'). This defence applies when:

▪ The medicine has been prescribed to treat a medical or dental problem; and

▪ You have taken it according to the instructions given by the prescriber and in the information provided with the medicine.

o Please note that it is still an offence to drive if you are unfit because of the medicine (i.e. your ability to drive is being affected).”

Details regarding a new driving offence concerning driving after drugs have been taken in the UK may be found here: https://www.gov.uk/drug-driving-law

4.8. Undesirable effects

The following frequency categories form the basis for classification of the undesirable effects:

Term

Frequency

Very common

≥ 1/10

Common

≥ 1/100 to < 1/10

Uncommon

≥ 1/1,000 to < 1/100

Rare

≥ 1/10,000 to < 1/1,000

Very rare

< 1/10,000

Not known

Frequency cannot be estimated from the available data

Immune system disorders:

Not known:

hypersensitivity (including oropharyngeal swelling), anaphylactic reactions

Metabolism and nutrition disorders

Common:

decreased appetite

Psychiatric disorders:

Common:

anxiety, confusional state, insomnia

Uncommon:

agitation, depression, euphoric mood, hallucinations, nightmares

Not known:

drug dependence (see section 4.4), dysphoria

Nervous system disorders:

Very common:

dizziness, somnolence

Common:

headache

Uncommon:

tremor, myoclonus, paraesthesia

Rare:

sedation, lethargy

Not known:

convulsions, dyskinesia, hyperalgesia (see section 4.4), central sleep apnoea syndrome

Eye disorders:

Uncommon:

visual impairment

Not known:

miosis

Cardiac disorders:

Rare:

bradycardia, palpitations, tachycardia

Vascular disorders:

Uncommon:

hypotension

Not known:

flushing

Respiratory, thoracic and mediastinal disorders:

Uncommon:

dyspnoea

Rare:

respiratory depression, bronchospasm

Gastrointestinal disorders:

Very common:

constipation, nausea

Common:

abdominal pain, dry mouth, vomiting

Uncommon:

dyspepsia, diarrhoea, dysgeusia

Not known:

paralytic ileus

Hepato-biliary disorders:

Uncommon:

hepatic enzymes increased

Rare:

elevation of pancreatic enzymes

Skin and subcutaneous tissue disorders:

Common:

pruritus, hyperhidrosis

Uncommon:

rash

Not known:

urticaria

Renal and urinary disorders:

Common:

urinary urgency

Uncommon:

urinary retention

Reproduction system and breast disorders:

Uncommon:

decreased libido, erectile dysfunction

General disorders and administration site conditions:

Common:

asthenia, injection site reactions

Uncommon:

drug withdrawal syndrome, fatigue, malaise, peripheral oedema

Very rare:

injection site induration (particularly after repeated s.c. administration)

Not known:

drug tolerance, drug withdrawal syndrome neonatal

Paediatric population:

For infants born to mothers receiving hydromorphone see section 4.6.

Description of selected adverse reactions

Drug dependence

Repeated use of Palladone injection can lead to drug dependence, even at therapeutic doses. The risk of drug dependence may vary depending on a patient's individual risk factors, dosage, and duration of opioid treatment (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Signs of hydromorphone intoxication and overdose include miosis, bradycardia, respiratory depression, hypotension, somnolence progressing to stupor and coma, and pneumonia aspiration. Circulatory failure and deepening coma may occur in more severe cases and may lead to a fatal outcome. Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.

Toxic leukoencephalopathy has been observed with hydromorphone overdose.

In unconscious patients with respiratory arrest intubation and assisted respiration may be required. An opioid antagonist (e.g. naloxone 0.4 mg) should be administered intravenously. Individual administration of the antagonist should be repeated at 2 to 3-minute intervals as necessary.

Close monitoring (at least for 24 hours) is required, since the effect of the opioid antagonist is shorter than that of hydromorphone, so that repeated occurrence of the signs of overdose like respiratory insufficiency are to be expected.

💬 Ask about this leaflet

Ask anything about Palladone 10 mg/ml solution for injection or infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →